![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Promethean | LSE:PTH | London | Ordinary Share | GB00B08H5G38 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.125 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:5430M PPL Therapeutics PLC 19 June 2003 Date: For immediate release: Thursday 19th June 2003 Contact: Geoff Cook, Chief Executive Officer Lindsay Dunsmuir, Chief Financial Officer PPL Therapeutics plc Telephone: 0131 440 4777 Alistair Mackinnon-Musson Philip Dennis Hudson Sandler Telephone: 020 7796 4133 Email: ppl@hspr.co.uk PPL Therapeutics plc PPL announces Fibrin I manufacturing Heads of Agreement with Instituto Grifols-Probitas Pharma Following yesterday's announcement regarding PPL's restructuring and the Company's focus on Fibrin I, PPL Therapeutics plc (PPL) is pleased to announce that it has today signed Heads of Agreement with Instituto Grifols S.A. (a company member of the holding Probitas Pharma) to manufacture Fibrin I using Grifols plasma derived fibrinogen. Under the agreement Grifols will scale up the Fibrin I manufacturing process to industrial scale and supply Fibrin I to PPL for clinical development and marketing. This agreement represents a critical step forward in PPL's development of Fibrin I as a surgical tissue sealant. Products in this class are used to seal tissue during surgery to prevent fluid or air leaks and in particular to stop bleeding. Fibrin I will offer a distinct competitive advantage in the rapidly growing market for tissue sealants as it is being developed as a liquid which is ready for the surgeon to use from the refrigerator, in contrast to existing fibrin sealants which require significant preparation before use. Grifols is a plasma products manufacturing company dedicated to the research, development and production of therapeutic proteins from human plasma according to the highest standards of quality and safety. Grifols uses the latest technology for protein purification. Its modern facilities are organised according to Good Manufacturing Procedures (GMP) and have been certified under the FDA "Establishment License" since 1995. Grifols has a fractionation capacity of over two million litres annually and is in the process of expansion which will result in the company taking its place amongst the largest plasma derivative companies in the world. PPL and Grifols expect to announce the signing of the full agreement based on these non-binding Heads of Agreement in the near future. The commercial terms of the agreement remain confidential. Geoff Cook, PPL's CEO said: "We are delighted to be able to announce this agreement with one of the world's leading and most respected plasma fractionators. Grifols quality standards and regulatory record together with their technology capability mean that they are the best possible partner for us in this area. In bringing any product to market which is based on a component of human plasma, the rigorous application of regulatory standards on quality and safety is critical. PPL, working together with Grifols on Fibrin I, will be able to put together a world class dossier for the regulatory authorities in Europe and the US." Notes to editors 1. Fibrin I is based on a fibrin monomer that is mixed with a neutralising buffer at the site of surgical application by means of a dual chamber syringe, where it polymerises to stop bleeding and seal tissue. It will be supplied as a liquid in pre-filled syringes and stored in the refrigerator, from where it is ready to be used. It is at least as effective as traditional fibrin sealants in sealing tissue and promoting haemostasis. Preclinical data suggests that the product may promote a more natural and rapid wound healing process than traditional fibrin sealants, which may reduce the potential for the formation of post surgical adhesions. An extensive patent portfolio provides comprehensive protection for the product in major markets until 2015 in the fields of haemostasis, tissue sealing, adhesion prevention and other biosurgery indications. 2. Further information about PPL, its products and technologies can be found at: www.ppl-therapeutics.com 3. Further information about Grifols, its products and technologies can be found at: www.grifols.com -------------------------- This information is provided by RNS The company news service from the London Stock Exchange END AGRSFDFIUSDSEFM
1 Year Promethean Chart |
1 Month Promethean Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions